Pacific Biosciences Lowers FY2026 Sales Guidance from $165.000M-$175.000M to $155.000M-$165.000M vs $166.790M Est

Benzinga Newsdesk www.benzinga.com Negative 96.2%

Neg 96.2% Neu 0% Pos 0%

Pacific Biosciences (NASDAQ:PACB) lowers FY2026 sales outlook from $165.000 million-$175.000 million to $155.000 million-$165.000 million vs $166.790 million estimate.